Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug

Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug Pulmazole is an inhaled anti-fungal formulation of itraconazole aimed at treating allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.

No comments:

Post a Comment